(Q42723597)

5 November 2017

title

Antifungal drugs: predicting clinical efficacy with pharmacodynamics (English)

1 reference

5 November 2017

1 reference

Michael D Nailor

1

1 reference

5 November 2017

Pranatharthi H Chandrasekar

series ordinal

2

1 reference

5 November 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

Expert Review of Clinical Pharmacology

5 November 2017

published in

1 reference

5 November 2017

volume

2

1 reference

5 November 2017

issue

4

1 reference

5 November 2017

page(s)

373-379

1 reference

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

5 November 2017

cites work

1 reference

Epidemiology of Candida species infections in critically ill non-immunosuppressed patients

21 January 2018

1 reference

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

21 January 2018

1 reference

Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.

21 January 2018

1 reference

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

21 January 2018

1 reference

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

21 January 2018

1 reference

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model

21 January 2018

1 reference

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

21 January 2018

1 reference

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

21 January 2018

1 reference

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

21 January 2018

1 reference

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

21 January 2018

1 reference

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

21 January 2018

1 reference

Development of resistance in candida isolates from patients receiving prolonged antifungal therapy

21 January 2018

1 reference

Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression

21 January 2018

1 reference

Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons

21 January 2018

1 reference

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients

21 January 2018

1 reference

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease

21 January 2018

1 reference

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse

21 January 2018

1 reference

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

21 January 2018

1 reference

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

21 January 2018

1 reference

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

21 January 2018

1 reference

Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models

21 January 2018

1 reference

Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of antifungals

21 January 2018

1 reference

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

21 January 2018

1 reference

High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial

21 January 2018

1 reference

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model

21 January 2018

1 reference

Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis

21 January 2018

1 reference

In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models

21 January 2018

1 reference

Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.

21 January 2018

1 reference

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.09.14

1 reference

5 November 2017

1 reference